Neoptolemos, J.P., Palmer, D.H., Ghaneh, P., Psarelli, E.E., Valle, J.W., Halloran, C.M., et al. (2017) Comparison of Adjuvant Gemcitabine and Capecitabine with Gemcitabine Monotherapy in Patients with Resected Pancreatic Cancer (ESPAC-4): A Multicenter, Open-Label, Randomized, Phase 3 Trial. The Lancet, 389, 1011-1024. https://doi.org/10.1016/S0140-6736(16)32409-6

has been cited by the following article:

• TITLE: Descriptive Study of Localized Pancreas Cancers: Experience of CHU Hassan II of Fes

  AUTHORS: Jihane Chouef, Lamiae Amaadour, Hajar Medyouni, Oumaima Siyouri, Samia Elhakym, Hafssa Elhilali, Karima Oualla, Zineb Benbrahim, Samia Arifi, Nawfel Mellas

  KEYWORDS: Pancreatic Cancer, Adenocarcinoma, Surgery, Adjuvant Chemotherapy

  JOURNAL NAME: Open Access Library Journal, Vol.11 No.4, April 23, 2024

  ABSTRACT: Pancreatic cancer is on the rise, ranking 13th among cancer sites in the world and 5th among digestive cancers. Real-life national data on patients with localized pancreatic adenocarcinoma are lacking in the medical literature given their number, which is often not representative because most diagnoses are made at the metastatic stage. The main objective of this study, which is part of the activity report of the Medical Oncology Department of the Hassan II University Hospital of Fez, is to report the survival results of localized pancreatic adenocarcinomas collected at the said department and to determine the prognostic factors associated with this survival depending on the year while comparing them to global results.